Crucell Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1. [verwijderd] 31 oktober 2006 22:05

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Biogen werd wel beloond voor de publicatie van sterke kwartaalcijfers. Het aandeel van het biotechnologiebedrijf
   schoot 8.27 procent omhoog, goed voor de eerste plaats in de Nasdaq.
   
2. [verwijderd] 31 oktober 2006 22:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   ruli schreef:

   Biogen werd wel beloond voor de publicatie van sterke kwartaalcijfers. Het aandeel van het biotechnologiebedrijf
   schoot 8.27 procent omhoog, goed voor de eerste plaats in de Nasdaq.
   
   

   Biogen Idec Posts 3Q Profit Surge
   (AP) BOSTON
   Shares of Biogen Idec Inc. rose 7 percent on Tuesday after its third-quarter profit beat Wall Street's expectations on strong sales of the biotechnology firm's two top-selling drugs.
   
   Biogen Idec also raised its earnings forecast for this year, and said its recent reintroduction of a multiple sclerosis drug that had been pulled from the market will accelerate growth in coming quarters.
   
   Although sales of that medication, Tysabri, totaled just $8 million in the July-September period, sales of an older MS drug, Avonex, rose 19 percent to $445 million. And Rituxan, a treatment for non-Hodgkins lymphoma and rheumatoid arthritis, posted a 12 percent gain, to $204 million.
   
   Cambridge-based Biogen Idec reported third-quarter net income of $156.6 million, or 45 cents per share, compared with a profit of $27.2 million, or 8 cents per share, in last year's third quarter, when it recorded big one-time charges for merger costs and severance expenses.
   
   Revenue rose 18 percent to $703.5 million from $596.2 million in the same period last year.
   
   Not counting one-time charges and stock option expenses, Biogen Idec's profit in the latest quarter was 60 cents per share, topping the average estimate of analysts surveyed by Thomson Financial, who expected earnings of 49 cents per share on revenue of $681.3 million.
   
   Shares of Biogen Idec rose $3.11 to $47.02 in afternoon trading on the Nasdaq Stock Market, where the stock has traded in a 52-week range of $38.93 to $50.72.
   
   Biogen Idec also raised its earnings forecast above $2.20 per share for the year, excluding one-time expenses and gains, up from the company's previous forecast for earnings of $1.95 to $2.10 per share. Analysts had forecast earnings of $2.09 per share.
   
   On a conference call with analysts, CEO James Mullen was optimistic about Tysabri's prospects.
   
   "We expect that as the Tysabri business gains momentum, we will see acceleration on the top line," Mullen said.
   
   More than 2,200 patients are being treated with the drug, which was initially introduced in late 2004, when some analysts projected the medication could eventually top $1 billion in annual sales.
   
   But just three months after the drug hit the market, Biogen Idec and its partner in Tysabri, Ireland's Elan Corp., withdrew it after two clinical trial patients died of a rare brain infection.
   
   U.S. and European authorities approved Tysabri's reintroduction in June, but with restrictions to monitor patients for symptoms of the brain disease, called PML. The once-a-month intravenous drug's return comes after dozens of MS patients pleaded with regulators to let them choose whether to take Tysabri - which has been shown to be more effective than older drugs for many patients - and accept the risk of contracting PML.
   
   Stephen Coleman, of Daedalus Capital LLC, a St. Louis-based investment firm whose holdings include Biogen Idec, said strong quarterly sales of Avonex and Rituxan indicate the company is healthy even without considering Tysabri's prospects.
   
   Coleman said Biogen Idec has plenty of work to restore doctors' and patients' confidence in Tysabri.
   
   "It's just going to take some time," he said. "I don't think it will take two to three years. I think it will take two to three quarters."
   
3. [verwijderd] 31 oktober 2006 22:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   flosz schreef:

   
   South Africa's last hardline white president dies
   Updated 10/31/2006 3:42 PM ET
   
   
   CAPE TOWN, South Africa (AP) — South Africa's last hardline white president P.W. Botha died late Tuesday, according to the South African Press Association. He was 90 years old.
   SAPA quoted security staff at his home on the southern Cape coast as saying that he died at 8 p.m. local time. Captain Frikkie Lucas said: "Botha died at home, peacefully."
   P.W Botha led the country through its worst racial violence and deepest international isolation.
   Known for his finger-wagging, confrontational style and nicknamed the "Old Crocodile" for his feared temper, Botha served as head of the white racist government from 1978 to 1989.
   Throughout his leadership he resisted mounting pressure to release South Africa's most famous political prisoner, Nelson Mandela, who was freed by Botha's successor, F.W. de Klerk in 1990.
   The Truth and Reconciliation Commission, a panel set up by Mandela's government to probe abuses, in 1998 concluded that Botha was guilty of gross human rights violations by ordering killings and bombings. But his failing health helped him escape prosecution and he spent his final years in seclusion in a seaside resort rather than in jail.
   Copyright 2006 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
   
   Posted 10/31/2006 3:37 PM ET
   
   www.usatoday.com/news/world/2006-10-3...
   

   Die kind wat dood geskiet is deur soldate by Nyanga
   
   Die kind is nie dood nie
   die kind lig sy vuiste teen sy moeder
   wat Afrika skreeu skreeu die geur van vryheid en heide
   in die lokasies van die omsingelde hart
   
   
   Die kind lig sy vuiste teen sy vader
   in die optog van die generasies
   wat Afrika skreeu skreeu die geur
   van geregtigheid en bloed
   in die strate van sy gewapende trots
   
   Die kind is nie dood nie
   nòg by Langa nòg by Nyanga
   nòg by Orlando nòg by Sharpville
   nòg by die polisiestasie in Philippi
   waar hy lê met 'n koeël deur sy kop
   
   Die kind is die skaduwee van die soldate
   op wag met gewere sarasene en knuppels
   die kind is teenwoordig by alle vergaderings en wetgewings
   die kind loer deur die vensters van huise en in die harte
   van moeders
   die kind wat net wou speel in die son by Nyanga is orals
   die kind wat 'n man geword het trek deur die ganse Afrika
   die kind wat 'n reus geword het reis deur die hele wêreld
   
   Sonder 'n pas
   Maart 1960
   
   Ingrid Jonker
   
   Vertaling Gerrit Komrij:
   Het kind dat doodgeschoten is door soldaten bij Nyanga
   
   Het kind is niet dood
   het kind heft zijn vuisten naar zijn moeder
   die Afrika schreeuwt de geur schreeuwt
   van vrijheid en heide
   in de townships van het omsingelde hart
   
   het kind heft zijn vuisten naar zijn vader
   in de optocht van de generaties
   die Afrika schreeuwen de geur schreeuwen
   van gerechtigheid en bloed
   in de straten van zijn gewapende trots
   
   Het kind is niet dood
   noch bij Langa noch bij Nyanga
   noch bij Orlando noch bij Sharpville
   noch bij het politiebureau van Philippi
   waar het ligt met een kogel door zijn hoofd
   
   Het kind is de schaduw van de soldaten
   op wacht met geweren pantserwagens en knuppels
   het kind is aanwezig bij alle vergaderingen en wetgevingen
   het kind loert door de vensters van huizen en in de harten
   van moeders
   het kind dat alleen maar wilde spelen in de zon bij Nyanga is overal
   het kind dat een man is geworden trekt door heel Afrika
   het kind dat een reus is geworden trekt door de gehele wereld
   
   Zonder pas
   
   *******************
   En ja Ian, ik ga nu slapen....
   gr.
   
4. [verwijderd] 31 oktober 2006 22:24

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Merck's risky bet on a little biotech
   Purchase of Sirna could lead to profitable cancer drugs, or nothing at all.
   By Aaron Smith, CNNMoney.com staff writer
   October 31 2006: 4:12 PM EST
   
   NEW YORK (CNNMoney.com) -- Merck's billion-dollar deal for Sirna could lead to profitable new drugs for treating cancer but the acquisition is a risky bet on a biotech with no proven products on the market, industry analysts said.
   
   Merck & Co., (down $0.17 to $45.47, Charts) the No. 4 U.S. drugmaker, agreed late Monday to buy Sirna Therapeutics (up $6.18 to $12.63, Charts), a San Francisco-based biotech, for $1.1 billion
   
   
   
   The price was about double the market value of Sirna, whose stock soared Tuesday. The deal is expected to close in the first quarter of 2007.
   
   Barbara Ryan, who tracks the drug industry for Deutsche Bank North America, said the purchase price reflects potential future earnings at Sirna had it remained independent. In a published note, Ryan called the deal a "smart move" because it demonstrates that Merck is "forward-looking and continues to make substantial and aggressive investments to fuel longer-term progress."
   
   But some analysts said that while buying biotechs with promising pipelines is key for big drugmakers that want to keep growing, the acquisition of Sirna comes with considerable risks.
   
   Battle over nerve pain heats up
   Merck and Pfizer (down $0.56 to $26.64, Charts), the world's largest drug company, have been buying up biotechs and licensing their experimental products, because their in-house research isn't enough to ensure sales growth. Big Pharma is under growing pressure to buy, discover or license new products to make up for patent losses on some of their top-selling products.
   
   So why exactly did Merck buy Sirna? Because the biotech specializes in RNA interference technology, also known as RNAi, which could conceivably be used to control gene activity to destroy cancer cells without harming healthy cells. In 2001, Merck bought another biotech, Rosetta Inpharmatics, which specializes in this "targeted" type of RNAi technology.
   
   Sirna has no products on the market. The most advanced experimental product in the biotech's pipeline, a potential treatment for a type of eye disease that can cause blindness, is years away from market approval, assuming its tests are successful. But that experimental product, called Sirna-072, is not the big draw for Merck, according to Ding Ding, analyst for Maxim Group.
   
   "I think Merck paid $1.1 billion in cash really to buy the technology platform," said Ding. "I'm not convinced that Merck is going to continue the current pipeline that Sirna has. The key pipeline that interests Merck is oncology."
   
   Merck could now find itself competing with Alnylam (up $3.06 to $19.66, Charts), another biotech that specializes in RNAi technology, said Ding. She added that Alnylam is an unlikely takeover target for Merck because it's already about 20 percent owned by the Swiss drug giant Novartis (up $0.41 to $60.81, Charts).
   
   Allos profit is two cancer drugs away
   Though the cancer industry has great potential, trying to develop profitable drugs with RNAi is risky. Jonathan Aschoff, analyst for Brean Murray, Carret & Co., said one of the biggest challenges in developing RNAi-based drugs is figuring out how to successfully deliver them to diseased parts of the body.
   
   "The delivery of these drugs is the Achilles' tendon of the RNAi industry," said Aschoff, who said they were being sent in what amounted to "unaddressed envelopes." But if Merck can overcome this hurdle, the company could have cancer drugs in the early stages of testing within two years, said Aschoff.
   
   But Les Funtleyder, analyst for Miller Tabak, said he was "skeptical" of Merck's acquisition, because its purchase of Rosetta had failed to produce tangible results in the last five years.
   
   "I still like Merck as a company and I think they're going to be fine, but I'm skeptical of the return potential of the deal," said Funtleyder.
   
   
5. danicole 31 oktober 2006 23:05

   auteur info

   • danicole

     Lid sinds: 18 aug 2005

     Laatste bezoek: 07 sep 2023

   • Aanbevelingen

     Ontvangen: 179

     Gegeven: 169

   •    Aantal posts: 529

   Toch wel iets om trots op te zijn:
   
   The Netherlands - a rising force in
   European biotechnology (uitgave September 2006)
   
   www.biotech-online.com/artimg/a200619...
   
6. am1993 31 oktober 2006 23:25

   auteur info

   • am1993

     Lid sinds: 13 jan 2004

     Laatste bezoek: 15 jun 2024

   • Aanbevelingen

     Ontvangen: 3634

     Gegeven: 6402

   •    Aantal posts: 5.446

   Flosz.
   Mooi. Zeker op z'n Zuid Afrikaans.
   Dank je.
   AM1993
7. [verwijderd] 1 november 2006 07:52

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   danicole schreef:

   Toch wel iets om trots op te zijn:
   
   The Netherlands - a rising force in
   European biotechnology (uitgave September 2006)
   
   www.biotech-online.com/artimg/a200619...
   
   

   Stukje:
   The Netherlands - a rising force in
   European biotechnology
   For many years the only significant European-based biotechnology centres
   that could hope to rival the world dominant US-based industry
   were located in the UK or in Germany. However, with the increasing realisation
   that knowledge-based economies are the only way in which
   Europe can hope to hold its own in increasingly competitive world markets,
   greater efforts have been undertaken to encourage biotechnology
   in other European countries and in particular The Netherlands. Triggered
   by government initiatives in 1999 the Dutch biotech world has thrived
   despite relatively adverse economic conditions over this period. The sector
   has shown double digit growth even though critical mass and economic
   viability still remain to be established in many start-up initiatives.
   The characteristic of the success of the fledging Dutch biotech
   industry appears to lie in the fruitful combination of high-class academic
   institutions with dynamic start-up companies and highly
   respected large multinationals. This powerful combination of academic
   and entrepreneurial initiatives is reminiscent of the famous pioneering
   spirit of the Dutch seafarers and traders of the seventeenth century. In
   this golden period, the Dutch created some of the first truly multinational
   trading enterprises and gave the Netherlands an economic clout
   and political reputation out of all proportion to its relatively small population.
   At this beginning of the twenty-first century, Dutch biotechnology
   is poised to reproduce the exploits of the past and have a greater
   impact on the modern scientific world than might be expected from a
   small European country of only 16 million inhabitants. In this article we
   take a look at just some of the highlights of Dutch biotechnology.
   
   DYNAMIC START-UPS
   
   With its corporate headquarters located in
   Leiden, and with R&D facilities in The
   Netherlands, Switzerland and Korea as well as
   manufacturing facilities in Switzerland,Korea
   and in Spain, Crucell (www.crucell.com) is
   one of the young Netherlands-based biotechnology
   companies with a high international
   profile. As a result of its recent acquisition of
   the Swiss vaccine company Berna, Crucell is
   now the leading independent vaccine production
   company and employs more than 900
   people throughout the world. The company
   has several unique technologies, amongst
   which is their PER.C6 cell line that is ideally
   suited for the development and large-scale
   manufacturing of a multitude of biopharmaceuticals.
   These include vaccines, antibodies,
   other therapeutic proteins and gene therapy
   products. Because of its wide applicability, the
   cell line has been licensed to a broad range of
   organisations and biopharmaceutical companies
   engaged in therapeutics development.
   The cell line itself originates from a single,
   human retina-derived cell, which has been
   deliberately immortalised using recombinant
   DNA technology.As a result, PER.C6 cells can
   replicate indefinitely, allowing them to be cultured
   in single cell suspension under serumfree
   conditions in quantities appropriate for
   large-scale manufacturing.
   The company's STAR technology is useful for
   increasing production of recombinant antibodies
   and therapeutic proteins on mammalian
   cell lines.Currently,more than 90% of
   all antibodies and therapeutic proteins are
   produced in derivatives of Chinese hamster
   ovary cells (CHO-K1 and CHO-DG44). The
   importance of the STAR technology can thus
   be seen from the fact that it has been successfully
   used to significantly increase yields in
   such cell lines.
8. [verwijderd] 1 november 2006 12:09

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Published online: 31 October 2006; | doi:10.1038/news061030-4
   Ancient human virus resurrected
   Virus from distant past may throw light on role of retroviruses in cancer.
   Researchers in France have recreated a 5-million-year-old virus whose remains are now found littered across the human genome. The ancient virus could help us to understand how these genetic remnants contribute to cancer.
   The virus is of a type called a retrovirus, which can insert copies of its genetic material into our own DNA. These viruses probably infected eggs and sperm of our primate ancestors many millions of years ago, and pasted numerous copies of their genetic material into the genome. The relics of these copies in human DNA are called human endogenous retroviruses, or HERVs.
   Today, copies of HERVs make up some 8% of our genetic code. But these copies have racked up mutations and are largely obsolete: scientists have never found one that can still convert itself into new, infectious virus particles.
   Now Thierry Heidmann at the Gustav Roussy Institute in Villejuif and his colleagues, have brought one of these retroviruses back to life. They call it Phoenix, for the mythical bird reborn from its own ashes.
   "It's a Jurassic Park kind of experiment to resurrect an old virus," says John Coffin who studies retroviruses at Tufts University in Boston, Massachusetts. "It's just kind of cool."
   
   Rising from the ashes
   Heidmann's team focused on a particular type of retrovirus that infected human cells less than 5 million years ago and left a legacy of some 30 copies of itself in the modern human genome. These duplicates have all become slightly different over time as they acquired various mutations. By comparing them, the researchers worked out the most likely sequence of the original virus from which they were copied.
   The team then used the DNA of two existing HERVs as a backbone and engineered specific mutations into it, to build a duplicate of the original Pheonix. They inserted it into human cells to see what it would do.
   The ancestral virus was able to copy itself and manufacture new virus particles, they found. And these particles could infect fresh cells and copy and paste its genes into these cells' genome.
   
   Dangerous infection
   The team also found hints that some of the HERVs in our genomes might still be infectious. They spliced together parts of three HERVs — a process that could occur spontaneously in a cell — and found that they could also produce infectious viruses. Heidmann says that the human genome may even harbour as-yet undiscovered HERVs that are naturally infectious.
   The ancient virus might help us understand whether and how retroviruses contribute to cancer, Coffin says. Researchers have found that cells of certain tumours contain retroviral proteins or whole viruses, as if a HERV has reactivated. Armed with the active virus, they'll be able to test whether infection actually accelerates the disease.
   The resurrection of an ancient, infectious virus is also likely to raise concerns, which Heidmann acknowledges. Last year, resurrection of the 1918 pandemic flu virus prompted fears about the virus's escape (see 'The 1918 flu virus is resurrected').
   Heidmann points out that the retrovirus is around 1,000 times less infectious than the famous HIV retrovirus. The group also engineered the virus so that it can only copy itself once and cannot proliferate out of control. "It's not impossible that it could turn out to be a pathogen but I think it's very unlikely," agrees Coffin.
   
   www.nature.com/news/2006/061030/full/...

   Bijlage:
9. aossa 1 november 2006 13:28

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 16 jun 2024

   • Aanbevelingen

     Ontvangen: 4041

     Gegeven: 3338

   •    Aantal posts: 17.606

   Héhé Roche gaat zijn wpa sneller later groeien dan zijn omzet. Zou het iets te doen hebben met STAR ?
   
   /quote new.cash.be/articles/index.jsp?siteID...
   
   12u20: Roche aan de dure kant 01 november 2006
   
   De omzet van farmaceut Roche is in het derde kwartaal met 20% gestegen tot CHF 10,5 miljard. Dit is bijna 3% beter dan de taxaties van analisten. Vooral de grootste kernactiviteit, geneesmiddelen, scoorde goed. De omzet van deze divisie nam met 25% toe. Roche kreeg veel vraag naar medicijnen tegen kanker. Ook het middel Tamiflu, dat gebruikt wordt tegen vogelgriep, vindt nog steeds gretig aftrek. Roche maakt op kwartaalbasis alleen omzetcijfers bekend. Voor zicht op de ontwikkeling van de winst zullen we geduld moeten hebben tot begin volgend jaar. Het concern heeft hierover wel alvast een tipje van de sluier opgelicht. Voor heel 2006 verwacht Roche voor zowel de geneesmiddelendivisie als voor het gehele concern een dubbelcijferige omzetgroei. Hiernaast zal de winst 'significant' hoger zijn dan in 2005. Het bedrijf hanteert als doelstelling om de winst per aandeel sneller te laten groeien dan de omzet. ABN Amro vindt het aandeel met een waardering van 21 keer de verwachte winst over 2007 aan de dure kant, zodat het neutraal advies gehandhaafd wordt. Bovendien is het concern voor een groot deel afhankelijk van slechts een klein aantal succesvolle medicijnen.
   
   [Modbreak Eric(forum@iex.nl): Duizenden berichten in één thread zorgt niet bepaald voor duidelijkheid. Daarom zetten we threads die meer dan 1.000 berichten hebben voort in een nieuwe thread: deel 2. Inmiddels is deel 2 begonnen op www.iex.nl/forum/topic.asp?forum=228&...